{"title":"Efficacy and safety of biliary stenting combined with <sup>125</sup>I seed implantation for the treatment of advanced extrahepatic cholangiocarcinoma.","authors":"Cai Cheng, Bo Wang, Chunmu Miao, Shengwei Li","doi":"10.3389/fsurg.2025.1608312","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The implantation of <sup>125</sup>I seed is expected to improve the prognosis of patients undergoing stent placement for advanced extrahepatic cholangiocarcinoma (eCCA), but its efficacy and safety remain unclear.</p><p><strong>Methods: </strong>Forty advanced eCCA patients who received percutaneous transhepatic biliary stenting (PTBS) (control group) and 40 PTBS combined with <sup>125</sup>I seed implantation (<sup>125</sup>I group) were retrospectively analyzed. Changes in serum biochemical indicators and tumor markers as well as the occurrence of complications were observed in the two groups, and the durations of stent patency and survival were compared.</p><p><strong>Results: </strong>The general information and preoperative baseline data did not significantly differ between the two groups (<i>P</i> < 0.05). Regardless of whether PTBS was combined with <sup>125</sup>I seed implantation, the ALT/AST levels of patients after operation were significantly lower, jaundice was relieved. And the improvements in postoperative liver function and jaundice in patients in <sup>125</sup>I group were better than those in control group. In addition, tumor markers in the two groups decreased significantly, and the decrease was more significant in patients in <sup>125</sup>I group. There was no significant difference in the total complication rate between the two groups. The stent patency time and overall survival of the patients in the <sup>125</sup>I group were longer than those in control group.</p><p><strong>Conclusion: </strong>Biliary stenting combined with <sup>125</sup>I seed implantation is a safe and effective treatment for patients with advanced eCCA, and it is superior to biliary stenting alone in improving liver function and prolonging the duration of stent patency and survival time.</p>","PeriodicalId":12564,"journal":{"name":"Frontiers in Surgery","volume":"12 ","pages":"1608312"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497782/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fsurg.2025.1608312","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The implantation of 125I seed is expected to improve the prognosis of patients undergoing stent placement for advanced extrahepatic cholangiocarcinoma (eCCA), but its efficacy and safety remain unclear.
Methods: Forty advanced eCCA patients who received percutaneous transhepatic biliary stenting (PTBS) (control group) and 40 PTBS combined with 125I seed implantation (125I group) were retrospectively analyzed. Changes in serum biochemical indicators and tumor markers as well as the occurrence of complications were observed in the two groups, and the durations of stent patency and survival were compared.
Results: The general information and preoperative baseline data did not significantly differ between the two groups (P < 0.05). Regardless of whether PTBS was combined with 125I seed implantation, the ALT/AST levels of patients after operation were significantly lower, jaundice was relieved. And the improvements in postoperative liver function and jaundice in patients in 125I group were better than those in control group. In addition, tumor markers in the two groups decreased significantly, and the decrease was more significant in patients in 125I group. There was no significant difference in the total complication rate between the two groups. The stent patency time and overall survival of the patients in the 125I group were longer than those in control group.
Conclusion: Biliary stenting combined with 125I seed implantation is a safe and effective treatment for patients with advanced eCCA, and it is superior to biliary stenting alone in improving liver function and prolonging the duration of stent patency and survival time.
期刊介绍：
Evidence of surgical interventions go back to prehistoric times. Since then, the field of surgery has developed into a complex array of specialties and procedures, particularly with the advent of microsurgery, lasers and minimally invasive techniques. The advanced skills now required from surgeons has led to ever increasing specialization, though these still share important fundamental principles.
Frontiers in Surgery is the umbrella journal representing the publication interests of all surgical specialties. It is divided into several “Specialty Sections” listed below. All these sections have their own Specialty Chief Editor, Editorial Board and homepage, but all articles carry the citation Frontiers in Surgery.
Frontiers in Surgery calls upon medical professionals and scientists from all surgical specialties to publish their experimental and clinical studies in this journal. By assembling all surgical specialties, which nonetheless retain their independence, under the common umbrella of Frontiers in Surgery, a powerful publication venue is created. Since there is often overlap and common ground between the different surgical specialties, assembly of all surgical disciplines into a single journal will foster a collaborative dialogue amongst the surgical community. This means that publications, which are also of interest to other surgical specialties, will reach a wider audience and have greater impact.
The aim of this multidisciplinary journal is to create a discussion and knowledge platform of advances and research findings in surgical practice today to continuously improve clinical management of patients and foster innovation in this field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
